|
Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. |
|
|
|
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche Pharma AG |
Consulting or Advisory Role - Accelsiors; AstraZeneca; Novartis |
Research Funding - GlaxoSmithKline; Novartis; Pfizer; Roche Pharma AG; Sanofi; Smiths Medical |
|
|
Honoraria - Amgen; Novartis; Roche Pharma AG |
Speakers' Bureau - Amgen; Novartis; Roche Pharma AG |
Travel, Accommodations, Expenses - Amgen; Novartis; Roche Pharma AG |
|
|
Honoraria - AstraZeneca; Pfizer; Roche Pharma AG |
Consulting or Advisory Role - Novartis; Roche Pharma AG |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Consulting or Advisory Role - Amgen |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Roche Pharma AG |
Research Funding - Amgen; Celgene; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Novartis; Roche Pharma AG |
Research Funding - Amgen; Celgene; Sanofi |
|
|
No Relationships to Disclose |
|
Elisabeth Melbinger-Zeinitzer |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen; AstraZeneca; Bayer; Merck; Pfizer; Roche Pharma AG; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Novartis; Roche Pharma AG; Teva |
Consulting or Advisory Role - Pierre Fabre |
Travel, Accommodations, Expenses - Roche Pharma AG; Teva |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Novartis; Pfizer; Roche Pharma AG |
Research Funding - Amgen; Celgene; Novartis; Roche Pharma AG |
Travel, Accommodations, Expenses - AstraZeneca; Roche Pharma AG; Teva |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Research Funding - Austrian Breast and Colorectal Cancer Study Group (Inst) |
|
|
No Relationships to Disclose |